Completed PHASE2 NCT01407887

Efficacy and Safety of Artesunate-amodiaquine-methylene for Malaria Treatment in Children

Efficacy and Safety of Artesunate-amodiaquine Combined With Methylene Blue for Falciparum Malaria Treatment in African Children

Sponsor: Heidelberg University

Conditions Uncomplicated Falciparum Malaria

Interventions artesunate (AS) - amodiaquine (AQ) - methylene blue (MB)

Updated 5 times since 2017 Last updated: Dec 4, 2012 Started: Aug 31, 2011 Primary completion: Aug 31, 2011 Completion: Dec 31, 2011

Listed as NCT01407887, this PHASE2 trial focuses on Uncomplicated Falciparum Malaria and remains completed. Sponsored by Heidelberg University, it has been updated 5 times since 2011, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Heidelberg University

Data source: Heidelberg University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nouna, Burkina Faso